Dear all
As I said I will not be able to attend the calls at this day and time. 
Jean Monlong from my group will bea ttending. He actually attended today 
as well
Roderic
  Dear all,
 Here are minutes of the Geuvadis analysis group TC on January 12.
 The next call has to be pushed forward by one week to *February 2 at 
 2pm. *We'll continue with the normal schedule after that, so the one 
 after that will be February 9.
 best regards,
 Tuuli
 Action items:
 - Tuuli:
     Set up a call for next week to discuss imputation details with 
 Natalja, Micha, Tim.
     Continue masked mapping tests
 - Esther, Peter, Natalja:
     Send an outline of you miRNA analysis pipeline to the analysis 
 group mailing list
 - Everyone:
     Think and discuss in your lab about the analyses that you'd want 
 to do (lead and/or participate) with this dataset, by the next call
 - Micha:
     Continue mapping tests
 - *Attending:* Tuuli, Micha, Esther, Ivo, Tim, Thomas x2, Mathias, 
 Peter, Olof, Matthias, Natalja
 - *Sequencing:* Most of the labs will be able to meet the initial 
 deadline of Feb 15 despite the delays in kit delivery, which is great. 
 We agreed to keep the very last deadline of March 15; all the samples 
 and reruns should be done and data submitted by then.
 - *Genotypes*: We need to impute about 40 samples that are not in 
 1000g Phase 1 (they have Omni 2.5M haplotypes). Natalia/EBI could 
 probably do this, and Tuuli, Micha and Tim & co. want to be 
 involved/informed too. This should be done within a month.
 - *miRNA analysis pipeline*: The labs who have experience of miRNA 
 analysis will send around details of how they map and quantify miRNAs. 
 We'll discuss on the next call how we should analyze them.
 - *A new collaboration:* Mark McMarthy from Oxford is a long-term 
 collaborator of Manolis. They've developed a new kind of a burden test 
 to look at rare variant effects, and expressed interest in doing some 
 analysis with the Geuvadis data. People were positive about this, and 
 Mark's postdoc Manuel Rivas will present their plans in a future TC.
 - *Analysis plans*: Tuuli would like to coordinate the future analyses 
 so that the essentials get done and there's no unnecessary overlaps. 
 For this we also need to assign people who will lead/participate/be 
 informed for each set of analysis. In the next call we'll start 
 putting together a list of what will be done and by whom.
 - *Analysis group face-to-face meeting*: It would be good to get 
 together to discuss in real life once the data is ready and gone 
 through basic pipelines - maybe around April.
 - *mRNA mapping*: The GEM paper will be submitted soon, so we might 
 want to use Micha's pipeline for mapping, quantification and 
 normalization as the basic approach. Micha presented some slides about 
 an approach that they're developing for SNP calling from RNAseq data, 
 based on excessive mapping. Tuuli presented results suggesting that 
 reference allele mapping bias affects exon quantifications. We should 
 correct for it e.g. by mapping to a masked reference.
 -- 
 Tuuli Lappalainen, PhD
 Department of Genetic Medicine and Development
 University of Geneva Medical School
 CMU / Rue Michel-Servet 1
 1211 Geneva 4
 Switzerland
 Tel. +41-(0)22-3795550
 tuuli.lappalainen(a)unige.ch 
-- 
(1) Centre de Regulacio Genomica
(2) Universitat Pompeu Fabra
Dr. Aiguader, 88 			+34 93 3160110 ph
E-08003 Barcelona			+34 93 3969983 fax
email: roderic.guigo(a)crg.cat		
http://big.crg.cat
RECOMB 2012 in Barcelona, 
http://recomb2012.crg.cat/
10 PhD fellowships, 
http://www.crg.eu/lacaixa_fellowships
3 fellowships for interdisciplinary post-doctoral studies
http://www.crg.es/interpod